What is Compass Therapeutics?
Compass Therapeutics, Inc. is dedicated to developing novel antibody-based therapeutics for various human diseases, with a primary focus on oncology. Headquartered in Boston, Massachusetts, the company was founded in 2014. Its pipeline includes promising candidates such as CTX-009, a bispecific antibody designed to block critical signaling pathways for angiogenesis and tumor vascularization, and CTX-471, an agonist of the CD137 co-stimulatory receptor on immune cells. Additionally, Compass Therapeutics is advancing CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1 checkpoint pathways. The company's strategic approach leverages advanced antibody engineering to address unmet needs in cancer treatment.
How much funding has Compass Therapeutics raised?
Compass Therapeutics has raised a total of $213.8M across 3 funding rounds:
Private Equity
$21.8M
Series A
$132M
Share Placement
$60M
Private Equity (2017): $21.8M, investors not publicly disclosed
Series A (2018): $132M led by OrbiMed, Cowen Healthcare Investments, Ulysses Diversified Holdings, Thiel Capital, Biomatics Capital, Borealis Ventures, F-Prime Capital Partners, Biomed Realty Ventures, and Alexandria Venture Investments
Share Placement (2020): $60M supported by Olivia Ventures
Key Investors in Compass Therapeutics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, and diagnostics. The firm's investment approach reflects a comprehensive understanding of healthcare innovation cycles and market dynamics, supporting companies at various stages of development.
Cowen Healthcare Investments
Cowen is an independent financial services firm offering investment banking, research, and investment management services. Founded in 1918 and headquartered in New York City, they provide a broad range of financial expertise.
Biomatics Capital
Biomatics Capital is a venture firm investing in data-enabled innovations at the intersection of healthcare and technology, aiming to support superior therapeutics and diagnostics through the convergence of genomics and digital data.
What's next for Compass Therapeutics?
The recent major strategic investment signifies a pivotal moment for Compass Therapeutics, likely positioning it for accelerated clinical development and potential expansion of its research initiatives. This substantial backing, part of its overall $213.8M in capital, suggests the company is entering a scaling phase, focusing on advancing its oncology pipeline through critical clinical trials. Future strategic moves may involve further partnerships, expanded research collaborations, and preparations for potential regulatory submissions, all aimed at bringing its innovative therapies to patients.
See full Compass Therapeutics company page
